Diagnosis of Recurrent Prostate Tumor at Multiparametric Prostate MRI: Pearls and Pitfalls

Size: px
Start display at page:

Download "Diagnosis of Recurrent Prostate Tumor at Multiparametric Prostate MRI: Pearls and Pitfalls"

Transcription

1 Diagnosis of Recurrent Prostate Tumor at Multiparametric Prostate MRI: Pearls and Pitfalls Mark Notley, MD; Jinxing Yu, MD; Ann S. Fulcher, MD; Mary A. Turner, MD; Don Nguyen, MD Virginia Commonwealth University Richmond, Virginia

2 Disclosures None

3 Objectives Demonstrate important MR features of recurrent prostate cancer (PCa) at multiparametric MR (Mp-MRI) Illustrate MR findings of mimics of recurrent PCa Present pathologically proven examples Emphasize clues for differentiating these mimics from recurrent PCa

4 Introduction Biochemical recurrence after treatment for PCa is a significant issue Overall recurrent PCa is noted in 23-42% following radical prostatectomy and 25-63% following radiation therapy Local recurrence is associated with a significantly increased risk for metastatic disease. Without salvage therapy, the average time from development of local recurrence to distant metastasis is approximately 3 years There is no reliable clinical way to diagnose local recurrence

5 Introduction Recent advances in MR techniques have markedly improved detection of local recurrence The proven cases in this poster include local recurrence following: Radical prostatectomy External beam radiation therapy Brachytherapy Cryotherapy High intensity focused ultrasound (HIFU) Laser treatment

6 Introduction A wide variety of entities can mimic recurrent PCa at Mp-MRI. These mimics include: Retained seminal vesicles Fibrotic scar Prominent periprostatic venous plexus Granulation tissue Focal areas of low T2 signal intensity Hypertrophic nodule in the central gland Hypertrophic fibromuscular stroma In this poster, we will discuss MR findings of recurrence and its mimics along with features that help to differentiate these mimics from recurrence The target audience for this poster are radiologists

7 Outline I. Key Features of Recurrent PCa at Mp-MRI following: II. MR Features of Mimics of Recurrence A. Retained seminal vesicles A. Radical prostatectomy B. Fibrotic scar B. External beam radiation therapy C. Brachytherapy D. Cryotherapy E. High intensity focused ultrasound C. Prominent periprostatic venous plexus D. Granulation tissue E. Focal areas of low T2 signal intensity F. Laser treatment F. Hypertrophic nodule in the central gland G. Hypertrophic fibromuscular stroma III. Summary and Clinical Implications

8 I. Key Features of Recurrent PCa at Mp-MRI A. Following radical prostatectomy Recurrent PCa in the surgical bed following radical prostatectomy is common, occurring in 23 to 42% Early detection of focal recurrence is crucial because these recurrences can be treated by external radiation with a good response The recurrence at T2WI has a slightly higher T2 signal intensity than that of adjacent musculature DCE yields important information since the majority of recurrences show rapid contrast wash in and wash out

9 I. Key Features of Recurrent PCa at Mp-MRI A. Following radical prostatectomy T2 DCE A B Recurrent PCa in the surgical bed. The patient is s/p radical prostatectomy with slowly rising PSA to 2.8. Axial T2 (A) shows a soft tissue mass (arrow) with slightly high T2 signal intensity. DCE (B) demonstrates the lesion in the surgical bed (arrow) with contrast wash in and out.

10 I. Key Features of Recurrent PCa at Mp-MRI B. Following external beam radiation therapy Recurrent PCa in patients after radiation therapy is common, ranging from 25 to 63% Accurate localization of recurrent local tumor allows for the possibility of reducing the target volume with salvage radiation therapy Diffusely low T2 signal intensity and indistinctness of normal zonal anatomy of prostate create diagnostic difficulty, particularly at T2WI The recurrence is usually; Commonly seen in the same location as the pre-treatment tumor A mass-like low T2 signal intensity nodule Diffusion restricted and abnormally enhanced

11 I. Key Features of Recurrent PCa at Mp-MRI B. Following external beam radiation therapy T2 DCE ADC A B C Recurrent PCa in the left apex. The patient is s/p external beam radiation therapy with recent elevation of PSA to 2.4. Axial T2 (A), DCE (B) and ADC map (C) demonstrate a lesion in the left apex (arrow) with nodular low T2 signal intensity (A), abnormal contrast wash in and out (B) and diffusion restriction (C), concerning for PCa. Targeted biopsy confirmed recurrent PCa Gleason score 7.

12 I. Key Features of Recurrent PCa at Mp-MRI C. Following brachytherapy T2WI and ADC maps are degraded by the radiation seeds In addition, diffusely low T2 signal intensity and indistinctness of normal zonal anatomy of the prostate present diagnostic difficulty, particularly at T2WI DCE is the single most important sequence in the diagnosis of recurrence in these patients Demonstrates rapid contrast wash in and wash out in the lesion

13 I. Key Features of Recurrent PCa at Mp-MRI C. Following brachytherapy DCE T2 A Recurrent PCa in the anterior aspect of the left central gland. The patient is s/p brachytherapy with recent elevation of PSA to 1.7. DCE (A) demonstrates a lesion in the anterior aspect of the left central gland (arrow) with contrast wash in and out. Axial T2 (B) shows no focal abnormality (arrow). MRI guided biopsy confirmed recurrent PCa Gleason score 7. B

14 I. Key Features of Recurrent PCa at Mp-MRI D. Following cryotherapy Cryotherapy ablates prostate tissue at very low temperatures After treatment, marked deformity of the prostate is noted as well as areas of necrosis resulting in a heterogeneous signal intensity on T2WI Recurrence following cryotherapy may show Low T2 signal intensity nodule with Diffusion restriction Rapid contrast wash in and wash out

15 I. Key Features of Recurrent PCa at Mp-MRI D. Following cryotherapy T2 DCE ADC A B C Recurrent PCa in the transitional zone. The patient is s/p cryotherapy with recent elevation of PSA to 1.5. Axial T2 (A), DCE (B) and ADC map (C) demonstrate a lesion in the transitional zone (arrow) with soft tissue nodular density on T2 (A), abnormal contrast wash in and out (B) and diffusion restriction (C). Targeted biopsy confirmed recurrent PCa Gleason score 8.

16 I. Key Features of Recurrent PCa at Mp-MRI E. Following high intensity focused ultrasound (HIFU) HIFU results in a cavitation effect - coagulation necrosis in the targeted prostate tissue Seen as areas of non-enhancing tissue in the treated region Residual or recurrent PCa following HIFU will show A region with low T2 signal intensity, diffusion restriction and abnormal enhancement

17 I. Key Features of Recurrent PCa at Mp-MRI E. Following HIFU T2 DCE ADC A B C Recurrent PCa in the anterior aspect of the right central gland. The patient is s/p HIFU with recent elevation of PSA to 4.1. Axial T2 (A), DCE (B) and ADC map (C) demonstrate a lesion in the anterior aspect of the right central gland (arrow) with low T2 signal (A), abnormal contrast wash in and out (B) and diffusion restriction (C). US/MRI fusion biopsy confirmed recurrent PCa Gleason score 7.

18 I. Key Features of Recurrent PCa at Mp-MRI F. Following laser treatment After placement of a light-sensitive agent into the prostate tissue, laser of a particular wavelength is applied and is absorbed by the photosensitizer This process creates reactive oxygen species in the adjacent prostate tissue and Results in cell destruction The residual or recurrent tumor following laser treatment is usually located in the periphery of the treated lesion and is seen as An area with low T2 signal intensity, diffusion restriction and early contrast wash in and wash out

19 II. MR Features of Mimics of Recurrence A. Retained seminal vesicles After radical prostatectomy, retained seminal vesicles are observed in approximately 20% of patients Retained seminal vesicles can be confused with recurrence most notably on CT and T1WI The retained seminal vesicles usually maintain their convoluted tubular appearance and have variable signal intensity on T2WI Retained seminal vesicles will not show rapid contrast wash in and wash out on DCE

20 II. MR Features of Mimics of Recurrence A. Retained seminal vesicles T2 DCE A B Retained seminal vesicle. The patient is s/p radical prostatectomy with slowly rising PSA to 0.9. Axial T2 (A) shows a homogeneous soft tissue density in the expected location of the right seminal vesicle (arrow). DCE (B) demonstrates no evidence of contrast wash out (arrow). MRI guided biopsy confirmed retained seminal vesicle, not a tumor.

21 II. MR Features of Mimics of Recurrence B. Fibrotic scar Fibrotic scar is commonly present in the surgical bed and is seen as low signal intensity on T2WI, mimicking a recurrence Fibrotic scar shows no or slightly delayed enhancement T2 T2 DCE A B C Fibrotic scar. The patient is s/p radical prostatectomy with a slowly rising PSA to 0.4. Axial T2 (A) and Coronal T2 (B) demonstrate a soft tissue density with low T2 signal in the left surgical bed. DCE (C) demonstrates no enhancement of the soft tissue density (arrow).

22 II. MR Features of Mimics of Recurrence C. Prominent venous plexus Prominent venous plexus demonstrates rapid contrast wash-in and wash-out, mimicking recurrence Located in the anterior and lateral aspects of the surgical bed Elongated and continuous DCE DCE A B Prominent venous plexus. The patient is s/p radical prostatectomy with a slowly rising PSA to 0.4. DCE (A, B) demonstrates an elongated and continuous structure in the lateral aspect of the surgical bed with contrast wash in and out (arrow) consistent with periprostatic vessels.

23 II. MR Features of Mimics of Recurrence D. Granulation tissue Granulation tissue in the surgical bed may show high signal on T2WI, mimicking local recurrence On DCE, it usually demonstrates no enhancement or only slight enhancement on delayed post contrast phases T2 DCE A B Granulation tissue. The patient is s/p radical prostatectomy with slowly rising PSA to 0.9. Axial T2 (A) shows a soft tissue density with slight high T2 signal (arrow) posterior to bladder. DCE (B) demonstrates no enhancement (arrow). MRI guided biopsy confirmed granulation tissue.

24 II. MR Features of Mimics of Recurrence E. Focal areas of low T2 signal intensity Following radiation therapy, focal areas of low T2 signal intensity are common due to post radiation changes or treated tumor - mimicking recurrence These areas may demonstrate normal diffusion restriction normal DCE

25 II. MR Features of Mimics of Recurrence E. Focal areas of low T2 signal intensity T2 DCE ADC A B C Focal areas of low T2 signal intensity. The patient is s/p external beam radiation therapy with a digital rectal exam demonstrating a nodule at the right mid prostate. Axial T2 (A) demonstrates two focal areas of low T2 signal intensity in the central gland (arrow) mimicking recurrence. DCE (B) and ADC map (C) demonstrate no abnormal enhancement (arrow) and no diffusion restriction (arrow) in these areas excluding recurrence.

26 II. MR Features of Mimics of Recurrence F. Hypertrophic nodule in the central gland Following radiation therapy, hypertrophic nodules in the central gland may demonstrate diffusion restriction and abnormal contrast wash in and out mimicking recurrence Clues for differentiating these nodules from recurrence include: Well-defined margins Different location from the original tumor Rapid contrast enhancement may be similar to the rest of the central gland

27 II. MR Features of Mimics of Recurrence F. Hypertrophic nodule in the central gland DCE T2 ADC A B C Hypertrophic nodule in the central gland. The patient is s/p external radiation therapy with a digital rectal exam demonstrating a nodule in the right mid prostate. DCE (A) demonstrates a large area of focal enhancement in the right central gland (arrow) mimicking a recurrence. Axial T2 (B) and ADC map (C) demonstrates that the enhancement corresponds to a well-defined nodule in the right central gland (arrow) without diffusion restriction (arrow). Biopsy confirmed benign prostatic tissue.

28 II. MR Features of Mimics of Recurrence G. Hypertrophic fibromuscular stroma Following radiation therapy, the fibromuscular stroma may be hypertrophic with low T2 signal intensity and diffusion restriction The stroma is usually located at the midline symmetric or nearly symmetric, without enhancement T2 ADC DCE A B C Hypertrophic fibromuscular stroma. The patient is s/p radiation therapy with recent elevation of PSA to 1.0. Axial T2 (A) and ADC map (B) demonstrate a low T2 signal intensity soft tissue mass in the anterior aspect of the central gland (arrow) near the midline with diffusion restriction (arrow). DCE (C) shows no enhancement of the mass. MRI guided biopsy confirmed benign fibromuscular stroma.

29 Summary and Clinical Implications Early diagnosis of local recurrence is important for treatment planning and is strongly associated with the patient s prognosis Extensive post treatment changes may make the diagnosis of recurrence challenging Advances of mp-mri often allow for differentiation of local recurrence from many mimics Attention to details of MR imaging features of recurrence and mimics allow one to arrive at a correct diagnosis and to avoid delays in treatment

30 References F.J. Bianco, P.T. Scardino, A.J. Stephenson, C.J. DiBlasio, P.A. Fearn and J.A. Eastham, Long term oncologic results of salvage radical prostatectomy for locally recurrent prostate cancer after radiotherapy, International Journal of Radiation Oncology, Biology, Physics, vol. 62, no. 2, pp , Kim CK, Park BK, Lee HM, Kim SS, Kim E.MRI techniques for prediction of local tumor progression after high-intensity focused ultrasonic ablation of prostate cancer. AJR Am J Roentgenol 2008 ; 190 ( 5 ): Sella T, Schwartz LH, Hricak H. Retained seminal vesicles after radical prostatectomy frequency, MRI characteristics, and clinical relevance. AJR Am J Roentgenol 2006 ; 186 ( 2 ): Hricak H, Carrington BM. MRI of the pelvis: a text atlas. London, England : Martin Dunitz, Vargas, H., Wassberg, C., Akin, O., & Hricak, H. (2012). MR Imaging of Treated Prostate Cancer. Radiology., 262(1), Sella T, Schwartz LH, Swindle PW, et al. Suspected local recurrence after radical prostatectomy: endorectal coil MR imaging. Radiology 2004 ; 231 ( 2 ): M.R. Moman, C.A.T. van den Berg, A.E. Bocken Kroger et al., Focal salvage guided by T2-weighted and dynamic contrast-enhanced magnetic resonance imaging for prostate cancer recurrences, International Journal of Radiation Oncology, Biology, Physics, vol. 76, no. 3, pp , Westphalen AC, Coakley FV, Roach M, McCulloch CE, Kurhanewicz J. Locally recurrent prostate cancer after external beam radiation therapy: diagnostic performance of 1.5-T endorectal MR imaging and MR spectroscopic imaging for detection. Radiology 2010; 256: Akin O, Gultekin DH, Vargas HA, et al. Incremental value of diffusion weighted and dynamic contrast enhanced MRI in the detection of locally recurrent prostate cancer after radiation treatment: preliminary results. Eur Radiol 2011 ; 21 ( 9 ): Yu J, Fulcher AS, Turner MA, Cockrell CH, Cote EP, Wallace TJ. Prostate cancer and its mimics at multiparametric prostate MRI. Br J Radiol May, 2014 Author correspondence: Mark Notley, MD mnotley@mcvh-vcu.edu

Beyond the PSA: Genomic Testing in Localized Prostate Cancer

Beyond the PSA: Genomic Testing in Localized Prostate Cancer Beyond the PSA: Genomic Testing in Localized Prostate Cancer Kelvin A. Moses, MD, PhD Vanderbilt University Medical Center Wednesday, December 2, 2015 5:00 p.m. ET/2:00 p.m. PT About ZERO ZERO s mission

More information

Prostate Cancer. Treatments as unique as you are

Prostate Cancer. Treatments as unique as you are Prostate Cancer Treatments as unique as you are UCLA Prostate Cancer Program Prostate cancer is the second most common cancer among men. The UCLA Prostate Cancer Program brings together the elements essential

More information

7. Prostate cancer in PSA relapse

7. Prostate cancer in PSA relapse 7. Prostate cancer in PSA relapse A patient with prostate cancer in PSA relapse is one who, having received a primary treatment with intent to cure, has a raised PSA (prostate-specific antigen) level defined

More information

SIGNPOSTS. Along the Pathway of Prostate Cancer. Understanding Diagnostic Tests and Procedures to Monitor Prostate Cancer

SIGNPOSTS. Along the Pathway of Prostate Cancer. Understanding Diagnostic Tests and Procedures to Monitor Prostate Cancer SIGNPOSTS Along the Pathway of Prostate Cancer Understanding Diagnostic Tests and Procedures to Monitor Prostate Cancer Your journey is unique like you. Signposts along the pathway can show you where you

More information

GENERAL CODING. When you review old cases that were coded to unknown, make corrections based on guidelines in effect at the time of diagnosis.

GENERAL CODING. When you review old cases that were coded to unknown, make corrections based on guidelines in effect at the time of diagnosis. GENERAL CODING When you review old cases that were coded to unknown, make corrections based on guidelines in effect at the time of diagnosis. Exception: You must review and revise EOD coding for prostate

More information

Real Time MRI guided Focal Laser Ablation Therapy for Prostate Cancer

Real Time MRI guided Focal Laser Ablation Therapy for Prostate Cancer Real Time MRI guided Focal Laser Ablation Therapy for Prostate Cancer A/Prof Celi Varol and Dr Orit Raz Uro-Oncologist Nepean and Macquarie Hospital Trial at Macquarie University Hospital Ethics board

More information

These rare variants often act aggressively and may respond differently to therapy than the more common prostate adenocarcinoma.

These rare variants often act aggressively and may respond differently to therapy than the more common prostate adenocarcinoma. Prostate Cancer OVERVIEW Prostate cancer is the second most common cancer diagnosed among American men, accounting for nearly 200,000 new cancer cases in the United States each year. Greater than 65% of

More information

Detection and staging of recurrent prostate cancer is still one of the important clinical problems in prostate cancer. A rise in PSA or biochemical

Detection and staging of recurrent prostate cancer is still one of the important clinical problems in prostate cancer. A rise in PSA or biochemical Summary. 111 Detection and staging of recurrent prostate cancer is still one of the important clinical problems in prostate cancer. A rise in PSA or biochemical recurrence (BCR) is the first sign of recurrent

More information

Robert Bristow MD PhD FRCPC

Robert Bristow MD PhD FRCPC Robert Bristow MD PhD FRCPC Clinician-Scientist and Professor, Radiation Oncology and Medical Biophysics, University of Toronto and Ontario Cancer Institute/ (UHN) Head, PMH-CFCRI Prostate Cancer Research

More information

Newly Diagnosed Prostate Cancer: Understanding Your Risk

Newly Diagnosed Prostate Cancer: Understanding Your Risk Newly Diagnosed Prostate Cancer: Understanding Your Risk When the urologist calls with the life-changing news that your prostate biopsy is positive for prostate cancer, an office appointment is made to

More information

Us TOO University Presents: Understanding Diagnostic Testing

Us TOO University Presents: Understanding Diagnostic Testing Us TOO University Presents: Understanding Diagnostic Testing for Prostate Cancer Patients Today s speaker is Manish Bhandari, MD Program moderator is Pam Barrett, Us TOO International Made possible by

More information

Prostate Cancer: Radiological Diagnosis, Staging, and Detection of Metastasis

Prostate Cancer: Radiological Diagnosis, Staging, and Detection of Metastasis Prostate Cancer: Radiological Diagnosis, Staging, and Detection of Metastasis Laura Rosow, HMS III Gillian Lieberman, MD BIDMC Core Clerkship in Radiology February 23, 2009 PACS, BIDMC Outline I. Index

More information

MR images of prostate cancer site and normal prostate after radical radiotherapy

MR images of prostate cancer site and normal prostate after radical radiotherapy MR images of prostate cancer site and normal prostate after radical radiotherapy Poster No.: C-1926 Congress: ECR 2015 Type: Scientific Exhibit Authors: J. Rembak-Szynkiewicz, K. Kansy, I. Gorczewska,

More information

Prostate cancer is the most common cause of death from cancer in men over age 75. Prostate cancer is rarely found in men younger than 40.

Prostate cancer is the most common cause of death from cancer in men over age 75. Prostate cancer is rarely found in men younger than 40. A.D.A.M. Medical Encyclopedia. Prostate cancer Cancer - prostate; Biopsy - prostate; Prostate biopsy; Gleason score Last reviewed: October 2, 2013. Prostate cancer is cancer that starts in the prostate

More information

CMScript. Member of a medical scheme? Know your guaranteed benefits! Issue 7 of 2014

CMScript. Member of a medical scheme? Know your guaranteed benefits! Issue 7 of 2014 Background CMScript Member of a medical scheme? Know your guaranteed benefits! Issue 7 of 2014 Prostate cancer is second only to lung cancer as the leading cause of cancer-related deaths in men. It is

More information

Oncology Annual Report: Prostate Cancer 2005 Update By: John Konefal, MD, Radiation Oncology

Oncology Annual Report: Prostate Cancer 2005 Update By: John Konefal, MD, Radiation Oncology Oncology Annual Report: Prostate Cancer 25 Update By: John Konefal, MD, Radiation Oncology Prostate cancer is the most common cancer in men, with 232,9 new cases projected to be diagnosed in the U.S. in

More information

PSA Screening for Prostate Cancer Information for Care Providers

PSA Screening for Prostate Cancer Information for Care Providers All men should know they are having a PSA test and be informed of the implications prior to testing. This booklet was created to help primary care providers offer men information about the risks and benefits

More information

Does my patient need more therapy after prostate cancer surgery?

Does my patient need more therapy after prostate cancer surgery? Does my patient need more therapy after prostate cancer surgery? Contact the GenomeDx Patient Care Team at: 1.888.792.1601 (toll-free) or e-mail: client.service@genomedx.com Prostate Cancer Classifier

More information

Functional MRI (DCE-MRI) in the follow-up of prostate cancer after beam radiotherapy (EBRT)

Functional MRI (DCE-MRI) in the follow-up of prostate cancer after beam radiotherapy (EBRT) Functional MRI (DCE-MRI) in the follow-up of prostate cancer after beam radiotherapy (EBRT) Poster No.: C-0748 Congress: ECR 2015 Type: Scientific Exhibit Authors: J. E. Méndez Escalante, D. Hernandez,

More information

Bard: Prostate Cancer Treatment. Bard: Pelvic Organ Prolapse. Prostate Cancer. An overview of. Treatment. Prolapse. Information and Answers

Bard: Prostate Cancer Treatment. Bard: Pelvic Organ Prolapse. Prostate Cancer. An overview of. Treatment. Prolapse. Information and Answers Bard: Prostate Cancer Treatment Bard: Pelvic Organ Prolapse Prostate Cancer An overview of Pelvic Treatment Organ Prolapse Information and Answers A Brief Overview Prostate Anatomy The prostate gland,

More information

Simultaneous 18 F Choline Positron Emission Tomography/Magnetic Resonance Imaging of the Prostate. Initial Results

Simultaneous 18 F Choline Positron Emission Tomography/Magnetic Resonance Imaging of the Prostate. Initial Results ORIGINAL ARTICLE Simultaneous 18 F Choline Positron Emission Tomography/Magnetic Resonance Imaging of the Prostate Initial Results Axel Wetter, MD,* Christine Lipponer, MD,* Felix Nensa, MD,* Karsten Beiderwellen,

More information

Review of Focal Therapy for Localized Prostate Cancer

Review of Focal Therapy for Localized Prostate Cancer Review of Focal Therapy for Localized Prostate Cancer Frances M. Martin and John F. Ward* Department of Urology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 2 PCRI Insights www.pcri.org

More information

Report with statistical data from 2007

Report with statistical data from 2007 2008 Cancer Program Annual Report with statistical data from 2007 Lake Cumberland Regional Hospital 305 Langdon Streett Somerset, KY 42503 Telephone: 606-679-7441 Fax: 606-678-9919 Cancer Committee Mullai,

More information

A Woman s Guide to Prostate Cancer Treatment

A Woman s Guide to Prostate Cancer Treatment A Woman s Guide to Prostate Cancer Treatment Supporting the man in your life Providing prostate cancer support and resources for women and families WOMEN AGAINST PROSTATE CANCER A Woman s Guide to Prostate

More information

Magnetic Resonance Imaging for Pre-Treatment Local Staging of Prostate Cancer

Magnetic Resonance Imaging for Pre-Treatment Local Staging of Prostate Cancer A Quality Initiative of the Program in Evidence-Based Care (PEBC), Cancer Care Ontario (CCO) Magnetic Resonance Imaging for Pre-Treatment Local Staging of Prostate Cancer M Haider, J Salerno, A Finelli,

More information

HEALTH NEWS PROSTATE CANCER THE PROSTATE

HEALTH NEWS PROSTATE CANCER THE PROSTATE HEALTH NEWS PROSTATE CANCER THE PROSTATE Prostate comes from the Greek meaning to stand in front of ; this is very different than prostrate which means to lie down flat. The prostate is a walnut-sized

More information

Advances in Prostate Imaging and Ablative Treatment of Prostate Cancer

Advances in Prostate Imaging and Ablative Treatment of Prostate Cancer Provided by the NYU Post-Graduate Medical School Advances in Prostate Imaging and Ablative Treatment of Prostate Cancer Friday Saturday June 19 20, 2015 New York City Register online: med.nyu.edu/cme/mi

More information

Prostate Cancer Guide. A resource to help answer your questions about prostate cancer

Prostate Cancer Guide. A resource to help answer your questions about prostate cancer Prostate Cancer Guide A resource to help answer your questions about prostate cancer Thank you for downloading this guide to prostate cancer treatment. We know that all the information provided online

More information

PROSTATE CANCER. Get the facts, know your options. Samay Jain, MD, Assistant Professor,The University of Toledo Chief, Division of Urologic Oncology

PROSTATE CANCER. Get the facts, know your options. Samay Jain, MD, Assistant Professor,The University of Toledo Chief, Division of Urologic Oncology PROSTATE CANCER Get the facts, know your options Samay Jain, MD, Assistant Professor,The University of Toledo Chief, Division of Urologic Oncology i What is the Prostate? Unfortunately, you have prostate

More information

Advances in Diagnostic and Molecular Testing in Prostate Cancer

Advances in Diagnostic and Molecular Testing in Prostate Cancer Advances in Diagnostic and Molecular Testing in Prostate Cancer Ashley E. Ross MD PhD Assistant Professor Urology, Oncology, Pathology Johns Hopkins School of Medicine September 24, 2015 1 Disclosures

More information

Your Health Matters. Localized Prostate Cancer and Its Treatment

Your Health Matters. Localized Prostate Cancer and Its Treatment Your Health Matters Localized Prostate Cancer and Its Treatment Greetings! Understanding prostate cancer and choosing among the various treatment options can be a difficult and anxiety-arousing process.

More information

An Introduction to PROSTATE CANCER

An Introduction to PROSTATE CANCER An Introduction to PROSTATE CANCER Being diagnosed with prostate cancer can be a life-altering experience. It requires making some very difficult decisions about treatments that can affect not only the

More information

Historical Basis for Concern

Historical Basis for Concern Androgens After : Are We Ready? Mohit Khera, MD, MBA Assistant Professor of Urology Division of Male Reproductive Medicine and Surgery Scott Department of Urology Baylor College of Medicine Historical

More information

Early Prostate Cancer: Questions and Answers. Key Points

Early Prostate Cancer: Questions and Answers. Key Points CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s Early Prostate Cancer:

More information

Metastatic Cervical Cancer s/p Radiation Therapy, Radical Hysterectomy and Attempted Modified Internal Hemipelvectomy

Metastatic Cervical Cancer s/p Radiation Therapy, Radical Hysterectomy and Attempted Modified Internal Hemipelvectomy Metastatic Cervical Cancer s/p Radiation Therapy, Radical Hysterectomy and Attempted Modified Internal Hemipelvectomy Sarah Hutto,, MSIV Marc Underhill, M.D. January 27, 2009 Past History 45 yo female

More information

Prostate Cancer In-Depth

Prostate Cancer In-Depth Prostate Cancer In-Depth Introduction Prostate cancer is the most common visceral malignancy among American men. In the year 2003, there are expected to be 220,000 new cases and nearly 29,000 deaths in

More information

Continuing Medical Education Article Imaging of Multiple Myeloma and Related Plasma Cell Dyscrasias JNM, July 2012, Volume 53, Number 7

Continuing Medical Education Article Imaging of Multiple Myeloma and Related Plasma Cell Dyscrasias JNM, July 2012, Volume 53, Number 7 Continuing Medical Education Article Imaging of Multiple Myeloma and Related Plasma Cell Dyscrasias JNM, July 2012, Volume 53, Number 7 Authors Ronald C. Walker 1,2, Tracy L. Brown 3, Laurie B. Jones-Jackson

More information

Prostatectomy, pelvic lymphadenect. Med age 63 years Mean followup 53 months No other cancer related therapy before recurrence. Negative.

Prostatectomy, pelvic lymphadenect. Med age 63 years Mean followup 53 months No other cancer related therapy before recurrence. Negative. Adjuvante und Salvage Radiotherapie Ludwig Plasswilm Klinik für Radio-Onkologie, KSSG CANCER CONTROL WITH RADICAL PROSTATECTOMY ALONE IN 1,000 CONSECUTIVE PATIENTS 1983 1998 Clinical stage T1 and T2 Mean

More information

Magnetic Resonance Imaging Targeted Biopsy of the Prostate

Magnetic Resonance Imaging Targeted Biopsy of the Prostate Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided

More information

OBJECTIVES By the end of this segment, the community participant will be able to:

OBJECTIVES By the end of this segment, the community participant will be able to: Cancer 101: Cancer Diagnosis and Staging Linda U. Krebs, RN, PhD, AOCN, FAAN OCEAN Native Navigators and the Cancer Continuum (NNACC) (NCMHD R24MD002811) Cancer 101: Diagnosis & Staging (Watanabe-Galloway

More information

PROSTATE CANCER 101 WHAT IS PROSTATE CANCER?

PROSTATE CANCER 101 WHAT IS PROSTATE CANCER? PROSTATE CANCER 101 WHAT IS PROSTATE CANCER? Prostate cancer is cancer that begins in the prostate. The prostate is a walnut-shaped gland in the male reproductive system located below the bladder and in

More information

Implementation Date: April 2015 Clinical Operations

Implementation Date: April 2015 Clinical Operations National Imaging Associates, Inc. Clinical guideline PROSTATE CANCER Original Date: March 2011 Page 1 of 5 Radiation Oncology Last Review Date: March 2015 Guideline Number: NIA_CG_124 Last Revised Date:

More information

HERC Coverage Guidance Advanced Imaging for Staging of Prostate Cancer Disposition of Public Comments

HERC Coverage Guidance Advanced Imaging for Staging of Prostate Cancer Disposition of Public Comments Table of Contents Commenters... 1 Public Comments... 2 References Provided by Commenters... 6 Commenters Identification Stakeholder A Medical Imaging & Technology Alliance (MITA), Arlington, VA [Submitted

More information

Prostate Cancer. What is prostate cancer?

Prostate Cancer. What is prostate cancer? Scan for mobile link. Prostate Cancer Prostate cancer is a tumor of the prostate gland, which is located in front of the rectum and below the bladder. Your doctor may perform a physical exam, prostate-specific

More information

Kim Mammen Abhinav Jaiswal Chris3an Medical College & Hospital Ludhiana India

Kim Mammen Abhinav Jaiswal Chris3an Medical College & Hospital Ludhiana India Kim Mammen Abhinav Jaiswal Chris3an Medical College & Hospital Ludhiana India } In the case of prostate cancer, a new, more conserva3ve form of monitoring called Ac3ve Surveillance is emerging which might

More information

Local Salvage Therapies After Failed Radiation for Prostate Cancer. Biochemical Failure after Radiation

Local Salvage Therapies After Failed Radiation for Prostate Cancer. Biochemical Failure after Radiation Local Salvage Therapies After Failed Radiation for Prostate Cancer James Eastham, MD Memorial Sloan-Kettering Cancer Center New York, New York Biochemical Failure after Radiation ASTRO criteria 3 consecutive

More information

Role of MRI in the Diagnosis of Prostate Cancer, A Proposal

Role of MRI in the Diagnosis of Prostate Cancer, A Proposal Clinical and Experimental Medical Sciences, Vol. 1, 2013, no. 3, 111 116 HIKARI Ltd, www.m-hikari.com Role of MRI in the Diagnosis of Prostate Cancer, A Proposal W. Akhter Research Fellow Urology, Bartshealth

More information

Update on Prostate Cancer: Screening, Diagnosis, and Treatment Making Sense of the Noise and Directions Forward

Update on Prostate Cancer: Screening, Diagnosis, and Treatment Making Sense of the Noise and Directions Forward Update on Prostate Cancer: Screening, Diagnosis, and Treatment Making Sense of the Noise and Directions Forward 33 rd Annual Internal Medicine Update December 5, 2015 Ryan C. Hedgepeth, MD, MS Chief of

More information

Prostate Cancer Action Plan: Choosing the treatment that s right for you

Prostate Cancer Action Plan: Choosing the treatment that s right for you Prostate Cancer Action Plan: Choosing the treatment that s right for you Segment 1: Introduction Trust me, there's a better way to choose a treatment for your prostate cancer. Watching this program is

More information

Prostate Cancer Screening. Dr. J. McCracken, Urologist

Prostate Cancer Screening. Dr. J. McCracken, Urologist Prostate Cancer Screening Dr. J. McCracken, Urologist USPSTF Lifetime risk for diagnosis currently estimated at 15.9% Llifetime risk of dying of prostate cancer is 2.8% Seventy percent of deaths due to

More information

PSA Testing 101. Stanley H. Weiss, MD. Professor, UMDNJ-New Jersey Medical School. Director & PI, Essex County Cancer Coalition. weiss@umdnj.

PSA Testing 101. Stanley H. Weiss, MD. Professor, UMDNJ-New Jersey Medical School. Director & PI, Essex County Cancer Coalition. weiss@umdnj. PSA Testing 101 Stanley H. Weiss, MD Professor, UMDNJ-New Jersey Medical School Director & PI, Essex County Cancer Coalition weiss@umdnj.edu September 23, 2010 Screening: 3 tests for PCa A good screening

More information

Analysis of Prostate Cancer at Easter Connecticut Health Network Using Cancer Registry Data

Analysis of Prostate Cancer at Easter Connecticut Health Network Using Cancer Registry Data The 2014 Cancer Program Annual Public Reporting of Outcomes/Annual Site Analysis Statistical Data from 2013 More than 70 percent of all newly diagnosed cancer patients are treated in the more than 1,500

More information

Case Number: RT2009-124(M) Potential Audiences: Intent Doctor, Oncology Special Nurse, Resident Doctor

Case Number: RT2009-124(M) Potential Audiences: Intent Doctor, Oncology Special Nurse, Resident Doctor Renal Cell Carcinoma of the Left Kidney Post Radical Surgery with pt4 Classification with Multiple Lung and Single Brain Metastases: the Role and Treatment Consideration of Radiotherapy Case Number: RT2009-124(M)

More information

A918: Prostate: adenocarcinoma

A918: Prostate: adenocarcinoma A918: Prostate: adenocarcinoma General facts of prostate cancer The prostate is about the size of a walnut. It is just below the bladder and in front of the rectum. The tube that carries urine (the urethra)

More information

Understanding the. Controversies of. testosterone replacement. therapy in hypogonadal men with prostate cancer. controversies surrounding

Understanding the. Controversies of. testosterone replacement. therapy in hypogonadal men with prostate cancer. controversies surrounding Controversies of testosterone replacement therapy in hypogonadal men with prostate cancer Samuel Deem, DO CULTURA CREATIVE (RF) / ALAMY Understanding the controversies surrounding testosterone replacement

More information

Metastatic Prostate Cancer Causing Complete Obstruction of the IVC

Metastatic Prostate Cancer Causing Complete Obstruction of the IVC Department of Radiology Henry Ford Health System Detroit, Michigan Metastatic Prostate Cancer Causing Complete Obstruction of the IVC Jennifer Johnston MSIII, Wayne State Medical School Stage 4 Metastatic

More information

Saturation Biopsy vs. 3D Spatial Biopsy vs. Free Hand Ultrasound biopsy for Targeted Prostate Cancer Therapies

Saturation Biopsy vs. 3D Spatial Biopsy vs. Free Hand Ultrasound biopsy for Targeted Prostate Cancer Therapies Saturation Biopsy vs. 3D Spatial Biopsy vs. Free Hand Ultrasound biopsy for Targeted Prostate Cancer Therapies John F. Ward, MD Assistant Professor University of Texas M. D. Anderson Cancer Center Ablation

More information

Roswell Park scientists and clinicians:

Roswell Park scientists and clinicians: The Prostate Cancer Center at Roswell Park Connects You to Nationally Recognized Experts for State-of-the-Art Treatment Options and Compassionate, Evidence-based Care Founded in 1898, Roswell Park Cancer

More information

Prostate Cancer Screening. A Decision Guide

Prostate Cancer Screening. A Decision Guide Prostate Cancer Screening A Decision Guide This booklet was developed by the U.S. Department of Health and Human Services, Centers for Disease Control and Prevention (CDC). Is screening right for you?

More information

Cancer doesn t care but we do. 2010 Cancer Annual Report

Cancer doesn t care but we do. 2010 Cancer Annual Report Cancer doesn t care but we do. 2010 Cancer Annual Report The Cancer Committee of CHRISTUS St. Patrick Hospital is proud to present its 2010 Annual Report. The Community Hospital Comprehensive Cancer Program

More information

Focal therapy for prostate cancer: seriously or seriously? Disclosures

Focal therapy for prostate cancer: seriously or seriously? Disclosures Focal therapy for prostate cancer: seriously or seriously? Mitchell Kamrava, MD Assistant Clinical Professor Department of Radiation Oncology University of California Los Angeles Disclosures Speaking honorarium

More information

FAQ About Prostate Cancer Treatment and SpaceOAR System

FAQ About Prostate Cancer Treatment and SpaceOAR System FAQ About Prostate Cancer Treatment and SpaceOAR System P. 4 Prostate Cancer Background SpaceOAR Frequently Asked Questions (FAQ) 1. What is prostate cancer? The vast majority of prostate cancers develop

More information

Questions to ask my doctor: About prostate cancer

Questions to ask my doctor: About prostate cancer Questions to ask my doctor: About prostate cancer Being diagnosed with prostate cancer can be scary and stressful. You probably have a lot of questions and concerns. Learning about the disease, how it

More information

Smoking and misuse of certain pain medicines can affect the risk of developing renal cell cancer.

Smoking and misuse of certain pain medicines can affect the risk of developing renal cell cancer. Renal cell cancer Renal cell cancer is a disease in which malignant (cancer) cells form in tubules of the kidney. Renal cell cancer (also called kidney cancer or renal adenocarcinoma) is a disease in which

More information

Choline PET/CT in Prostate Cancer Imaging

Choline PET/CT in Prostate Cancer Imaging Choline PET/CT in Prostate Cancer Imaging Tara Barwick Consultant in Radiology & Nuclear Medicine, Imperial College Healthcare NHS Trust, London Honorary Clinical Senior Lecturer, Division of Cancer, Imperial

More information

Prostate Cancer Screening. A Decision Guide for African Americans

Prostate Cancer Screening. A Decision Guide for African Americans Prostate Cancer Screening A Decision Guide for African Americans This booklet was developed by the U.S. Department of Health and Human Services, Centers for Disease Control and Prevention (CDC). Published

More information

GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER

GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER BY Ali Shamseddine, MD (Coordinator); as04@aub.edu.lb Fady Geara, MD Bassem Shabb, MD Ghassan Jamaleddine, MD CLINICAL PRACTICE GUIDELINES FOR THE TREATMENT

More information

magnetic resonance imaging, prostatic neoplasms, watchful waiting

magnetic resonance imaging, prostatic neoplasms, watchful waiting Magnetic Resonance Imaging for Predicting Prostate Biopsy Findings in Patients Considered for Active Surveillance of Clinically Low Risk Prostate Cancer Hebert Alberto Vargas,*, Oguz Akin, Asim Afaq, Debra

More information

Corporate Medical Policy Intensity-Modulated Radiation Therapy (IMRT) of the Prostate

Corporate Medical Policy Intensity-Modulated Radiation Therapy (IMRT) of the Prostate Corporate Medical Policy Intensity-Modulated Radiation Therapy (IMRT) of the Prostate File Name: Origination: Last CAP Review: Next CAP Review: Last Review: intensity_modulated_radiation_therapy_imrt_of_the_prostate

More information

Current and Future Trends in Proton Treatment of Prostate Cancer

Current and Future Trends in Proton Treatment of Prostate Cancer Current and Future Trends in Proton Treatment of Prostate Cancer Reinhard W. Schulte Assistant Professor Department of Radiation Medicine Loma Linda University Medical Center Loma Linda, CA, USA Outline

More information

Localised prostate cancer

Localised prostate cancer Diagnosis Specialist Nurses 0800 074 8383 prostatecanceruk.org 1 Localised prostate cancer In this fact sheet: What is localised prostate cancer? How is localised prostate cancer diagnosed? What do my

More information

Kidney Cancer OVERVIEW

Kidney Cancer OVERVIEW Kidney Cancer OVERVIEW Kidney cancer is the third most common genitourinary cancer in adults. There are approximately 54,000 new cancer cases each year in the United States, and the incidence of kidney

More information

Understanding Prostate Cancer. The Urology Group Guide for Newly Diagnosed Patients. Advanced Care. Improving Lives.

Understanding Prostate Cancer. The Urology Group Guide for Newly Diagnosed Patients. Advanced Care. Improving Lives. Understanding Prostate Cancer The Urology Group Guide for Newly Diagnosed Patients Advanced Care. Improving Lives. UNDERSTANDING PROSTATE CANCER The Urology Group has created this publication to provide

More information

A PATIENT S GUIDE TO ABLATION THERAPY

A PATIENT S GUIDE TO ABLATION THERAPY A PATIENT S GUIDE TO ABLATION THERAPY THE DIVISION OF VASCULAR/INTERVENTIONAL RADIOLOGY THE ROBERT WOOD JOHNSON UNIVERSITY HOSPITAL Treatment options for patients with cancer continue to expand, providing

More information

The Expanding Role of. MRI in Prostate Cancer

The Expanding Role of. MRI in Prostate Cancer Genitourinary Imaging Review Murphy et al. MRI in Prostate Cancer Genitourinary Imaging Review Gillian Murphy 1 Masoom Haider 2 Sangeet Ghai 1 oraiah Sreeharsha 2 Murphy G, Haider M, Ghai S, Sreeharsha

More information

Targeted Focal (Subtotal) Therapy for Early Stage Prostate Cancer

Targeted Focal (Subtotal) Therapy for Early Stage Prostate Cancer Targeted Focal (Subtotal) Therapy for Early Stage Prostate Cancer Duke K. Bahn, MD Prostate Institute of America (www.pioa.org) Ventura, California 888-234-0004 Published in PAACT newsletter Introduction:

More information

PATIENT GUIDE. Localized Prostate Cancer

PATIENT GUIDE. Localized Prostate Cancer PATIENT GUIDE Localized Prostate Cancer The prostate* is part of the male reproductive system. It is about the same size as a walnut and weighs about an ounce. As pictured in Figure 1, the prostate is

More information

Antonio Rampoldi Struttura Complessa di Radiologia Interventistica Azienda Ospedale Niguarda Ca Granda, Milano. Terminology

Antonio Rampoldi Struttura Complessa di Radiologia Interventistica Azienda Ospedale Niguarda Ca Granda, Milano. Terminology Biophysical principles and clinical applications of MRgFUS Alberto Torresin Struttura Complessa di Fisica Sanitaria Azienda, Milano Università degli Studi di Milano Dip. di Fisica Antonio Rampoldi Struttura

More information

PRODYNOV. Targeted Photodynamic Therapy of Ovarian Peritoneal Carcinomatosis ONCO-THAI. Image Assisted Laser Therapy for Oncology

PRODYNOV. Targeted Photodynamic Therapy of Ovarian Peritoneal Carcinomatosis ONCO-THAI. Image Assisted Laser Therapy for Oncology PRODYNOV Targeted Photodynamic Therapy of Ovarian Peritoneal Carcinomatosis ONCO-THAI Image Assisted Laser Therapy for Oncology Inserm ONCO-THAI «Image Assisted Laser Therapy for Oncology» Inserm ONCO-THAI

More information

Secondary Cancer and Relapse Rates Following Radical Prostatectomy for Prostate-Confined Cancer

Secondary Cancer and Relapse Rates Following Radical Prostatectomy for Prostate-Confined Cancer Copyright E 2007 Journal of Insurance Medicine J Insur Med 2007;39:242 250 MORTALITY Secondary Cancer and Relapse Rates Following Radical Prostatectomy for Prostate-Confined Cancer David Wesley, MD; Hugh

More information

Clinical Trials and Radiation Treatment. Gerard Morton Odette Cancer Centre Sunnybrook Research Institute University of Toronto

Clinical Trials and Radiation Treatment. Gerard Morton Odette Cancer Centre Sunnybrook Research Institute University of Toronto Clinical Trials and Radiation Treatment Gerard Morton Odette Cancer Centre Sunnybrook Research Institute University of Toronto What I will cover.. A little about radiation treatment The clinical trials

More information

Prostate Cancer. Patient Information

Prostate Cancer. Patient Information Prostate Cancer Patient Information 1 The Prostate & Prostate Cancer The prostate is a small gland in the male reproductive system, approximately the size and shape of a walnut. It is located directly

More information

For further information on screening and early detection of prostate cancer, see the Section entitled Screening for Prostate Cancer.

For further information on screening and early detection of prostate cancer, see the Section entitled Screening for Prostate Cancer. Prostate Cancer For many older men, prostate cancer may be present but never cause symptoms or problems and many men will die with their prostate cancer rather than of their prostate cancer. Yet it remains

More information

Appendix 2. Patient information

Appendix 2. Patient information Appendix 2. Patient information Original document: "Comprendre le cancer de la prostate. Guide d information et de dialogue à l'usage des personnes malades et de leurs proches (http://www.sor-cancer.fr),

More information

Prostate Cancer & Its Treatment

Prostate Cancer & Its Treatment Your Health Matters Prostate Cancer & Its Treatment By the UCSF Medical Center Prostate Cancer Advocates Greetings! From our personal experience in dealing with our own prostate cancers, we UCSF Patient

More information

Gleason Score. Oncotype DX GPS. identified for. about surveillance. time to get sophisticated

Gleason Score. Oncotype DX GPS. identified for. about surveillance. time to get sophisticated patient: MARK SMITH PSA 6.2 Gleason Score 6 Oncotype DX GPS 8 identified for active surveillance time to get sophisticated about surveillance Accurate prediction of prostate cancer risk is needed at the

More information

DIAGNOSIS OF PROSTATE CANCER

DIAGNOSIS OF PROSTATE CANCER DIAGNOSIS OF PROSTATE CANCER Determining the presence of prostate cancer generally involves a series of tests and exams. Before starting the testing process, the physician will ask questions about the

More information

NEW HYBRID IMAGING TECHNOLOGY MAY HAVE BIG POTENTIAL FOR IMPROVING DIAGNOSIS OF PROSTATE CANCER

NEW HYBRID IMAGING TECHNOLOGY MAY HAVE BIG POTENTIAL FOR IMPROVING DIAGNOSIS OF PROSTATE CANCER Media Release April 7, 2009 For Immediate Release NEW HYBRID IMAGING TECHNOLOGY MAY HAVE BIG POTENTIAL FOR IMPROVING DIAGNOSIS OF PROSTATE CANCER London, Ontario Improved hybrid imaging techniques developed

More information

Treating Localized Prostate Cancer A Review of the Research for Adults

Treating Localized Prostate Cancer A Review of the Research for Adults Treating Localized Prostate Cancer A Review of the Research for Adults Is this information right for me? Yes, this information is right for you if: Your doctor * said all tests show you have localized

More information

MODULE 8: PROSTATE CANCER: SCREENING & MANAGEMENT

MODULE 8: PROSTATE CANCER: SCREENING & MANAGEMENT MODULE 8: PROSTATE CANCER: SCREENING & MANAGEMENT KEYWORDS: Prostate cancer, PSA, Screening, Radical Prostatectomy LEARNING OBJECTIVES At the end of this clerkship, the medical student will be able to:

More information

Case Report. Central Neurocytoma. Fotis Souslian, MD; Dino Terzic, MD; Ramachandra Tummala, MD. Department of Neurosurgery, University of Minnesota

Case Report. Central Neurocytoma. Fotis Souslian, MD; Dino Terzic, MD; Ramachandra Tummala, MD. Department of Neurosurgery, University of Minnesota 1 Case Report Central Neurocytoma Fotis, MD; Dino Terzic, MD; Ramachandra Tummala, MD Department of Neurosurgery, University of Minnesota Case This is a previously healthy 20 year old female, with 3 months

More information

Diffuse infiltration in multiple myeloma treatment response assessment with "total-spine" contrast enhanced MR imaging

Diffuse infiltration in multiple myeloma treatment response assessment with total-spine contrast enhanced MR imaging Diffuse infiltration in multiple myeloma treatment response assessment with "total-spine" contrast enhanced MR imaging Poster No.: C-0276 Congress: ECR 2011 Type: Scientific Paper Authors: P. P. Arcuri,

More information

MRI of Bone Marrow Radiologic-Pathologic Correlation

MRI of Bone Marrow Radiologic-Pathologic Correlation MRI of Bone Marrow Radiologic-Pathologic Correlation Marilyn J. Siegel, M.D. Mallinckrodt Institute of Radiology Washington University School of Medicine St. Louis, MO and Visiting Scientist, AFIP, Washington,

More information

.org. Metastatic Bone Disease. Description

.org. Metastatic Bone Disease. Description Metastatic Bone Disease Page ( 1 ) Cancer that begins in an organ, such as the lungs, breast, or prostate, and then spreads to bone is called metastatic bone disease (MBD). More than 1.2 million new cancer

More information

IGRT. IGRT can increase the accuracy by locating the target volume before and during the treatment.

IGRT. IGRT can increase the accuracy by locating the target volume before and during the treatment. DERYA ÇÖNE RADIOTHERAPY THERAPIST ACIBADEM KOZYATAGI HOSPITAL RADIATION ONCOLOGY DEPARTMENT IGRT IGRT (image-guided radiation therapy) is a technique that reduces geometric uncertainties by considering

More information

AFTER DIAGNOSIS: PROSTATE CANCER Understanding Your Treatment Options

AFTER DIAGNOSIS: PROSTATE CANCER Understanding Your Treatment Options AFTER DIAGNOSIS: PROSTATE CANCER Understanding Your Treatment Options INTRODUCTION This booklet describes how prostate cancer develops, how it affects the body and the current treatment methods. Although

More information

Malignant Pleural Diseases Advances Clinicians Should Know F Gleeson

Malignant Pleural Diseases Advances Clinicians Should Know F Gleeson Malignant Pleural Diseases Advances Clinicians Should Know F Gleeson The following relevant disclosures, conflicts of interest and/ or financial relationships exist related to this presentation: Consultant

More information

Characterization of small renal lesions: Problem solving with MRI Gary Israel, MD

Characterization of small renal lesions: Problem solving with MRI Gary Israel, MD Characterization of small renal lesions: Problem solving with MRI Gary Israel, MD With the widespread use of cross-sectional imaging, many renal masses are incidentally found. These need to be accurately

More information

High Intensity Focused Ultrasound for Prostate Cancer

High Intensity Focused Ultrasound for Prostate Cancer High Intensity Focused Ultrasound for Prostate Cancer Patient Information Exploring a Minimally Invasive Prostate Cancer Therapy The Choice for HIFU Worldwide A Patient s Guide to Prostate Cancer and Sonablate

More information